In response to growing demand from external healthcare stakeholders for a complete and differentiated evidence package, the top 20 pharma companies have responded by creating formal business processes around integrated evidence planning (IEP). ZS produced the industry’s first “State of IEP” benchmarking report in 2022, and in 2024 we refreshed that analysis by meeting with medical and evidence generation leaders across 16 different pharma organizations.
In this webinar we meet with Jack Goodpasture, SVP Global Medical Affairs Capabilities and Transformation at Eli Lilly, to discuss the key insights and learnings of the IEP analysis and Eli Lilly’s multiyear transformation journey in integrated evidence generation.
Watch this webinar to:
- Hear strategies that leaders can use to realize the promise of integrated evidence
- Discover what leaders at top pharma and life sciences companies revealed about their integrated evidence strategy and maturity
- Unlock the potential of end-to-end integrated evidence capabilities via enhanced business processes aligned with digital integrated evidence plans
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
